{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:01:59Z","timestamp":1793746919499,"version":"4.6.1"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"30","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MRC UKRI CARP","award":["MR\/T005181\/1"],"award-info":[{"award-number":["MR\/T005181\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Pathogenic variation in genes encoding proteins of the cardiac sarcomere is responsible for 30%\u201340% of cases of hypertrophic cardiomyopathy. The main clinical utility of genetic testing is to provide diagnostic confirmation and facilitation of family screening. It also assists in the detection of aetiologies, which require distinct monitoring and treatment approaches. Other clinical applications, including the use of genetic information to inform risk prediction models, have been limited by the challenge of establishing robust genotype\u2013phenotype correlations with actionable consequences, but new data on the interaction between rare and common genetic variation, as well as the emergence of therapies targeting disease-specific pathogenic mechanisms, herald a new era for genetic testing in routine practice.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehae421","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T09:45:58Z","timestamp":1720604758000},"page":"2727-2734","source":"Crossref","is-referenced-by-count":126,"title":["Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6408-4667","authenticated-orcid":false,"given":"Luis R","family":"Lopes","sequence":"first","affiliation":[{"name":"Barts Heart Centre, St. Bartholomew\u2019s Hospital , West Smithfield, London EC1A 7BE , UK"},{"name":"Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London , 5 University St, London WC1E 6JF , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y","family":"Ho","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M","family":"Elliott","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, St. Bartholomew\u2019s Hospital , West Smithfield, London EC1A 7BE , UK"},{"name":"Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London , 5 University St, London WC1E 6JF , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"2024080915564129800_ehae421-B1","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pcad.2023.04.009","article-title":"Evolution of genetic testing and gene therapy in hypertrophic cardiomyopathy","volume":"80","author":"Chiswell","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"2024080915564129800_ehae421-B3","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-I","article-title":"A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation","volume":"62","author":"Geisterfer-Lowrance","year":"1990","journal-title":"Cell"},{"key":"2024080915564129800_ehae421-B4","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1136\/heartjnl-2014-305645","article-title":"A straightforward guide to the sarcomeric basis of cardiomyopathies","volume":"100","author":"Lopes","year":"2014","journal-title":"Heart"},{"key":"2024080915564129800_ehae421-B5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/ng1295-434","article-title":"Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy","volume":"11","author":"Watkins","year":"1995","journal-title":"Nat Genet"},{"key":"2024080915564129800_ehae421-B6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0092-8674(94)90054-X","article-title":"Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere","volume":"77","author":"Thierfelder","year":"1994","journal-title":"Cell"},{"key":"2024080915564129800_ehae421-B7","doi-asserted-by":"crossref","first-page":"e002460","DOI":"10.1161\/CIRCGEN.119.002460","article-title":"Evaluating the clinical validity of hypertrophic cardiomyopathy genes","volume":"12","author":"Ingles","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"2024080915564129800_ehae421-B8","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.110.972828","article-title":"DNA sequencing: clinical applications of new DNA sequencing technologies","volume":"125","author":"Dewey","year":"2012","journal-title":"Circulation"},{"key":"2024080915564129800_ehae421-B9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"2024080915564129800_ehae421-B10","doi-asserted-by":"crossref","first-page":"e0203422","DOI":"10.1371\/journal.pone.0203422","article-title":"Heterozygous junctophilin-2 (JPH2) p.(Thr161Lys) is a monogenic cause for HCM with heart failure","volume":"13","author":"Vanninen","year":"2018","journal-title":"PLoS One"},{"key":"2024080915564129800_ehae421-B11","doi-asserted-by":"crossref","first-page":"104079","DOI":"10.1016\/j.ejmg.2020.104079","article-title":"The p.(Cys150Tyr) variant in CSRP3 is associated with late-onset hypertrophic cardiomyopathy in heterozygous individuals","volume":"63","author":"Salazar-Mendiguchia","year":"2020","journal-title":"Eur J Med Genet"},{"key":"2024080915564129800_ehae421-B12","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.jacc.2018.10.001","article-title":"Formin homology 2 domain containing 3 (FHOD3) is a genetic basis for hypertrophic cardiomyopathy","volume":"72","author":"Ochoa","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B13","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/eurheartj\/ehab424","article-title":"Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy","volume":"42","author":"Lopes","year":"2021","journal-title":"Eur Heart J"},{"key":"2024080915564129800_ehae421-B14","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2020-316913","article-title":"Mutations in TRIM63 cause an autosomal-recessive form of hypertrophic cardiomyopathy","volume":"106","author":"Salazar-Mendiguch\u00eda","year":"2020","journal-title":"Heart"},{"key":"2024080915564129800_ehae421-B15","first-page":"3461","article-title":"Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes","volume":"38","author":"Walsh","year":"2017","journal-title":"Eur Heart J"},{"key":"2024080915564129800_ehae421-B16","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1093\/eurheartj\/ehad372","article-title":"Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy","volume":"44","author":"Allouba","year":"2023","journal-title":"Eur Heart J"},{"key":"2024080915564129800_ehae421-B17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.hrthm.2022.03.1225","article-title":"European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) expert consensus statement on the state of genetic testing for cardiac diseases","volume":"19","author":"Wilde","year":"2022","journal-title":"Heart Rhythm"},{"key":"2024080915564129800_ehae421-B18","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Authors\/Task Force members","year":"2014","journal-title":"Eur Heart J"},{"key":"2024080915564129800_ehae421-B19","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cardfail.2018.03.004","article-title":"Genetic evaluation of cardiomyopathy\u2014a Heart Failure Society of America practice guideline","volume":"24","author":"Hershberger","year":"2018","journal-title":"J Card Fail"},{"key":"2024080915564129800_ehae421-B20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCULATIONAHA.123.065987","article-title":"Meta-analysis of penetrance and systematic review on transition to disease in genetic hypertrophic cardiomyopathy","volume":"149","author":"Topriceanu","year":"2024","journal-title":"Circulation"},{"key":"2024080915564129800_ehae421-B21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2020.06.011","article-title":"Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers","volume":"76","author":"Lorenzini","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jacc.2021.07.017","article-title":"Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy","volume":"78","author":"de Marvao","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/ehjci\/jey095","article-title":"Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers","volume":"19","author":"Groarke","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2024080915564129800_ehae421-B24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/CIRCGENETICS.109.862128","article-title":"Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy","volume":"2","author":"Ho","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"2024080915564129800_ehae421-B25","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1161\/01.CIR.0000019070.70491.6D","article-title":"Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy","volume":"105","author":"Ho","year":"2002","journal-title":"Circulation"},{"key":"2024080915564129800_ehae421-B26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/CIRCIMAGING.112.000333","article-title":"T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy","volume":"6","author":"Ho","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2024080915564129800_ehae421-B27","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003026","article-title":"Ultrasonic assessment of myocardial microstructure in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy","volume":"9","author":"Hiremath","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2024080915564129800_ehae421-B28","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.amjcard.2018.08.008","article-title":"Multilayer myocardial mechanics in genotype-positive left ventricular hypertrophy-negative patients with hypertrophic cardiomyopathy","volume":"122","author":"Williams","year":"2018","journal-title":"Am J Cardiol"},{"key":"2024080915564129800_ehae421-B29","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","article-title":"Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy","volume":"41","author":"Crilley","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B30","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa1002659","article-title":"Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy","volume":"363","author":"Ho","year":"2010","journal-title":"N Engl J Med"},{"key":"2024080915564129800_ehae421-B31","doi-asserted-by":"crossref","first-page":"e020227","DOI":"10.1161\/JAHA.120.020227","article-title":"Myocardial perfusion defects in hypertrophic cardiomyopathy mutation carriers","volume":"10","author":"Hughes","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2024080915564129800_ehae421-B32","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.123.063835","article-title":"Microstructural and microvascular phenotype of sarcomere mutation carriers and overt hypertrophic cardiomyopathy","volume":"148","author":"Joy","year":"2023","journal-title":"Circulation"},{"key":"2024080915564129800_ehae421-B33","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jacc.2024.01.006","article-title":"Electrophysiological characterization of subclinical and overt hypertrophic cardiomyopathy by magnetic resonance imaging-guided electrocardiography","volume":"83","author":"Joy","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B34","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jamacardio.2017.2352","article-title":"Role of genetic testing in inherited cardiovascular disease: a review","volume":"2","author":"Cirino","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2024080915564129800_ehae421-B35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ogc.2017.10.009","article-title":"Preimplantation genetic screening and preimplantation genetic diagnosis","volume":"45","author":"Sullivan-Pyke","year":"2018","journal-title":"Obstet Gynecol Clin North Am"},{"key":"2024080915564129800_ehae421-B36","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJM199204233261703","article-title":"Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy","volume":"326","author":"Watkins","year":"1992","journal-title":"N Engl J Med"},{"key":"2024080915564129800_ehae421-B37","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1161\/CIRCULATIONAHA.110.954446","article-title":"Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy","volume":"122","author":"Landstrom","year":"2010","journal-title":"Circulation"},{"key":"2024080915564129800_ehae421-B38","first-page":"23","article-title":"Perspectives on current recommendations for genetic testing in HCM","volume":"2018","author":"Monserrat","year":"2018","journal-title":"Glob Cardiol Sci Pract"},{"key":"2024080915564129800_ehae421-B39","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jacc.2014.09.059","article-title":"Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations","volume":"64","author":"Coppini","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B40","doi-asserted-by":"crossref","first-page":"e005191","DOI":"10.1161\/CIRCHEARTFAILURE.118.005191","article-title":"Incident atrial fibrillation is associated with MYH7 sarcomeric gene variation in hypertrophic cardiomyopathy","volume":"11","author":"Lee","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2024080915564129800_ehae421-B41","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/heartjnl-2014-306387","article-title":"Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy","volume":"101","author":"Lopes","year":"2015","journal-title":"Heart"},{"key":"2024080915564129800_ehae421-B42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0025-6196(11)60890-2","article-title":"Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy","volume":"83","author":"Olivotto","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2024080915564129800_ehae421-B43","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"2024080915564129800_ehae421-B44","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","article-title":"Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry","volume":"74","author":"Neubauer","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B45","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/CIRCGEN.120.002929","article-title":"Spatial and functional distribution of MYBPC3 pathogenic variants and clinical outcomes in patients with hypertrophic cardiomyopathy","volume":"13","author":"Helms","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"2024080915564129800_ehae421-B46","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1136\/heartjnl-2012-301995","article-title":"New approaches to the clinical diagnosis of inherited heart muscle disease","volume":"99","author":"Lopes","year":"2013","journal-title":"Heart"},{"key":"2024080915564129800_ehae421-B47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.118.038846","article-title":"Yield of clinical screening for hypertrophic cardiomyopathy in child first-degree relatives","volume":"140","author":"Norrish","year":"2019","journal-title":"Circulation"},{"key":"2024080915564129800_ehae421-B48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"2024080915564129800_ehae421-B49","doi-asserted-by":"crossref","first-page":"e016614","DOI":"10.1161\/JAHA.120.016614","article-title":"Specific therapy for transthyretin cardiac amyloidosis: a systematic literature review and evidence-based recommendations","volume":"9","author":"Marques","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2024080915564129800_ehae421-B50","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/heartjnl-2016-310138","article-title":"Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy","volume":"103","author":"Rosmini","year":"2017","journal-title":"Heart"},{"key":"2024080915564129800_ehae421-B51","doi-asserted-by":"crossref","first-page":"e002905","DOI":"10.1161\/CIRCGEN.120.002905","article-title":"Cryptic splice-altering variants in MYBPC3 are a prevalent cause of hypertrophic cardiomyopathy","volume":"13","author":"Lopes","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"2024080915564129800_ehae421-B52","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacc.2018.04.078","article-title":"Whole genome sequencing improves outcomes of genetic testing in patients with hypertrophic cardiomyopathy","volume":"72","author":"Bagnall","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B53","doi-asserted-by":"crossref","first-page":"e002783","DOI":"10.1161\/CIRCGEN.119.002783","article-title":"Reevaluation of the south Asian MYBPC3(Delta25bp) intronic deletion in hypertrophic cardiomyopathy","volume":"13","author":"Harper","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"2024080915564129800_ehae421-B54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper","year":"2021","journal-title":"Nat Genet"},{"key":"2024080915564129800_ehae421-B55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41588-020-00762-2","article-title":"Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect","volume":"53","author":"Tadros","year":"2021","journal-title":"Nat Genet"},{"key":"2024080915564129800_ehae421-B56","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamacardio.2022.1061","article-title":"Rare and common genetic variation underlying the risk of hypertrophic cardiomyopathy in a national biobank","volume":"7","author":"Biddinger","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2024080915564129800_ehae421-B57","doi-asserted-by":"crossref","first-page":"e001768","DOI":"10.1161\/CIRCGENETICS.117.001768","article-title":"A comparison of whole genome sequencing to multigene panel testing in hypertrophic cardiomyopathy patients","volume":"10","author":"Cirino","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"2024080915564129800_ehae421-B58","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacc.2013.03.062","article-title":"Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy","volume":"62","author":"Olivotto","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamacardio.2019.4268","article-title":"Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy","volume":"5","author":"Fumagalli","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2024080915564129800_ehae421-B60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ehjqcco\/qcac006","article-title":"Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy\/Myocarditis Registry","volume":"9","author":"Lopes","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2024080915564129800_ehae421-B61","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehy625","article-title":"The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy","volume":"40","author":"Wasserstrum","year":"2019","journal-title":"Eur Heart J"},{"key":"2024080915564129800_ehae421-B62","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1161\/CIRCULATIONAHA.121.053527","article-title":"Time to think differently about sarcomere-negative hypertrophic cardiomyopathy","volume":"143","author":"Watkins","year":"2021","journal-title":"Circulation"},{"key":"2024080915564129800_ehae421-B63","doi-asserted-by":"crossref","first-page":"e001620","DOI":"10.1161\/CIRCGENETICS.116.001620","article-title":"Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"2024080915564129800_ehae421-B64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2017.79","article-title":"Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup","volume":"20","author":"Ko","year":"2018","journal-title":"Genet Med"},{"key":"2024080915564129800_ehae421-B65","doi-asserted-by":"crossref","first-page":"12607","DOI":"10.1073\/pnas.1309493110","article-title":"Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human beta-cardiac myosin motor function","volume":"110","author":"Sommese","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024080915564129800_ehae421-B66","doi-asserted-by":"crossref","first-page":"e24634","DOI":"10.7554\/eLife.24634","article-title":"Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes","volume":"6","author":"Alamo","year":"2017","journal-title":"Elife"},{"key":"2024080915564129800_ehae421-B67","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2024080915564129800_ehae421-B68","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"2024080915564129800_ehae421-B69","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2024080915564129800_ehae421-B70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B71","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2024080915564129800_ehae421-B72","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024080915564129800_ehae421-B73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.repc.2019.03.008","article-title":"New perspectives in the pharmacological treatment of hypertrophic cardiomyopathy","volume":"39","author":"Malt\u00eas","year":"2020","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"2024080915564129800_ehae421-B74","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jacbts.2021.07.012","article-title":"Translation of new and emerging therapies for genetic cardiomyopathies","volume":"7","author":"Helms","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"2024080915564129800_ehae421-B75","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2024080915564129800_ehae421-B76","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"key":"2024080915564129800_ehae421-B77","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41569-023-00853-7","article-title":"Detection of subclinical hypertrophic cardiomyopathy","volume":"20","author":"Joy","year":"2023","journal-title":"Nat Rev Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/30\/2727\/58789534\/ehae421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/30\/2727\/58789534\/ehae421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T21:00:51Z","timestamp":1723237251000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/30\/2727\/7710314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":77,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2024,7,10]]},"published-print":{"date-parts":[[2024,8,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae421","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8,7]]},"published":{"date-parts":[[2024,7,10]]}}}